Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE
Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract
Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial
Invited Commentary “Unraveling the Potential of Water-Free Cyclosporine in Dry Eye Disease.
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
Further contribution to the discussion on perfluorohexyloctane eye drops in dry eye disease.
Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease.
A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent.
Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape.
Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease
NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study
Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial
NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study
A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study
Results of the Randomized Phase 2B/3 ESSENCE study with CyclASol 0.1% for treatment of dry eye disease
Randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease
Semi-fluorinated Alkane Eye Drops Reduce Signs and Symptoms of Evaporative Dry Eye Disease After Cataract Surgery
Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial
Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections
Preclinical Studies Evaluating the Effect of Semifluorinated Alkanes on Ocular Surface and Tear Fluid Dynamics
Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study
A Clinical Phase 2 Study to Assess Efficacy, Safety and Tolerability of CyclASol® for Treatment of Dry Eye Disease (DED)
Semifluorinated alkane based systems for enhanced corneal penetratoin of poorly soluble drugs
A Low concentration of Tacrolismus /Semifluorinate Alkane (SFA) Eyedrop suppresses intraocular inflammation in experimental models of uveitis
A Semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic options for topical treatment of dry eye
Semifluorinated Alkanes and Alkanes-A Phase Study of the Perfluorohexyloctane – Tetradecane System
Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease
Influence of Aging on Severity and Anti-Inflammatory Treatment of Experimental Dry Eye Disease
Semifluorinated alkane eye drops for treatment of dry eye disease
